The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma
Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, comments on features that are characterized as genomically aggressive or indolent in patients with smoldering myeloma, and discusses their impact on progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
